Background
==========

Thyroid carcinoma is the most common endocrine malignancy and a common cancer among the malignancies of head and neck. It comprises 91.5% of all endocrine malignancies and 1% of all malignant diseases \[[@B1]\]. An estimated 33550 new cases are diagnosed annually in the United States and recent statistics shows the incidence of thyroid carcinoma has increased, especially in papillary thyroid carcinomas (PTC) \[[@B2]\]. PTC is the most common type, which accounts for 80% of all thyroid cancers \[[@B3]\]. Early accurate diagnosis and timely treatment are critical for improving long-term survival of PTC patients. Many diagnostic tools have been used for thyroid carcinoma, such as sonography, computed tomography, magnetic resonance imaging, cytological examination and fine-needle aspiration. Currently, although ultrasound-guided fine-needle aspiration biopsy is considered as the most effective test for distinguishing malignant from benign thyroid nodules, its sensitivity is approximately 93% and its specificity is 75% \[[@B4]\]. At the same time, researchers have been seeking valuable biomarkers for thyroid carcinoma diagnosis, such as galectin-3, fibronectin-1, CITED-1, HBME1, cytokeratin-19 and TPO, and so on. What is disappointing is that all these biomarkers either are lacking specificity to some degree, or have a poor positive predictive value \[[@B5]-[@B9]\]. To distinguish a malignant thyroid nodule from a benign lesion more accurately, the diagnostic test, however, still needs to be improved. Moreover, a noninvasive screening method for thyroid malignancy remains unavailable.

Recent advances in the proteomics study have introduced novel techniques for the screening of cancer biomarkers and improved early and accurate diagnosis of cancer diseases to a new horizon \[[@B10]\]. Surfaced enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS), which generates the protein fingerprint by MS, has been proved a powerful tool for potential biomarker discovery \[[@B11],[@B12]\]. Recently, the SELDI-TOF-MS analysis has been successfully used to identify specific biomarkers for various cancers, such as ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, breast cancer, *etc*\[[@B13]-[@B17]\]. In search of biomarkers for diagnosing PTC, a few pilot studies based on proteomics were conducted, in which SELDI-TOF-MS has been utilized \[[@B18],[@B19]\]. However, no specific protein biomarkers have been identified and validated in those reports.

In this study, firstly, we used SELDI-TOF-MS technology to screen potential protein patterns specific for PTC and then purified the candidate protein biomarker peaks by HPLC, identified by LC-MS/MS and finally confirmed these biomarkers by ProteinChip Immunoassays. To the best of our knowledge, this is the first time that proteins biomarkers have been identified for PTC.

Results
=======

Serum protein profiles and data processing
------------------------------------------

Serum samples from the training set were analyzed and compared by SELDI-TOF-MS with WCX2 chip. All MS data were baseline subtracted and normalized using total ion current, and the peak clusters were generated by Biomarker Wizard software. After carrying out Wilcoxon rank sum tests to determine relative signal strength, 26 peaks with *p*value \< 0.01 were obtained. Seven protein peaks were found up-regulated and 19 peaks were found down-regulated in PTC group (data not shown). From the random combination of protein peaks with remarkable variation, support vector machine (SVM) screened out the combined model with maximum Youden index of the predicted value, identifying 3 markers positioned at 9190, 6631 and 8697 respectively. In the PTC group, the 9190 Da protein was remarkably elevated while 6631 & 8697 Da proteins were significantly decreased (figure [1](#F1){ref-type="fig"}). The descriptive statistics of these 3 markers are shown in Table [1](#T1){ref-type="table"}. In addition, the level of 9190 Da protein progressively increased with the clinical stage I, II, III and IV, and the expression of 6631, 8697 Da proteins gradually decreased in higher stages (figure [2](#F2){ref-type="fig"}). Combining 3 potential markers, using the method of leave-1-out for cross detection, the sensitivity of discriminating 60 PTC and 40 normal subjects was 98%, and its specificity was 97%.

###### 

The relative peak intensity of three distinct protein spectra found in sera of PTC patients.

  --------------------------------------------------------------------------
  ***m/z***   **Patients with PTC**\   **Healthy Individuals**\   ***p***
              **(mean ± SD)**          **(mean ± SD)**            
  ----------- ------------------------ -------------------------- ----------
  9190        6853.82 ± 1585.23        282.46 ± 118. 09           0.000538

  6631        2706.56 ± 578.17         4697.16 ± 989.85           0.001381

  8697        3017.98 ± 600.28         4924.32 ± 1048.11          0.001672
  --------------------------------------------------------------------------

![**A representative mapping of SELDI-TOF-MS analysis of sera from PTC patients and healthy controls**. Differentially expressed proteins with potential diagnostic significance are arrowed. Top-group denotes sera from patients with PTC, in which the protein with *m*/*z*of 9190 Da was over-expressed. Bottom-group denotes sera from healthy individuals, in which the proteins with *m*/*z*of 6631 and 8697 Da were up-regulated.](1476-4598-8-79-1){#F1}

![**A representative mapping of SELDI-TOF-MS analysis from different stages of PTC patients and non-cancer controls**. The level of the 9190 Da protein progressively increased with the clinical stage I, II, III and IV, and the expression of 6631 and 8697 Da proteins gradually decreased in higher stages.](1476-4598-8-79-2){#F2}

Protein peak validation
-----------------------

The remaining 48 PTC and 76 control serum samples (20 healthy controls and 56 patients with benign thyroid node) as a blind testing set, were analyzed to validate the accuracy and validity of the classification model derived from the training set. The descriptive statistics of the three markers in 48 PTC patients and 76 non-cancer controls are shown in Table [2](#T2){ref-type="table"}. The classification model distinguished the PTC samples from controls with a sensitivity of 95.15%, specificity of 93.97%, and positive predictive value of 96.0%, respectively. The area under the receiver operating characteristics (ROC) curve of this model was 0.971.

###### 

The descriptive statistics of these 3 markers in the blind testing set.

  --------------------------------------------------------------------------
  ***m/z***   **Patients with PTC**\   **Non-cancer Controls**\   ***p***
              **(mean ± SD)**          **(mean ± SD)**            
  ----------- ------------------------ -------------------------- ----------
  9190        6798.89 ± 1517.76        271.35 ± 102.04            0.000526

  6631        2786.03 ± 596.11         4705.23 ± 991.45           0.001402

  8697        3011.62 ± 598.13         4912.36 ± 1042.79          0.001669
  --------------------------------------------------------------------------

Purification and identification of candidate protein biomarkers
---------------------------------------------------------------

Serum samples from PTC patients were used for the purification of the up-regulated candidate protein biomarker (9190 Da), and serum samples from healthy controls were used for the purification of the two down-regulate proteins (6631, 8697 Da) using WCX SPE and C18 HPLC. Figure [3](#F3){ref-type="fig"} shows the results of MALDI-TOF-MS analysis of the three purified candidate protein biomarkers.

![**MALDI-TOF-MS spectra of three purified potential protein markers**.](1476-4598-8-79-3){#F3}

After digestion with modified trypsin, the peptide mixture was analyzed by nano-LC-MS/MS. Figure [4](#F4){ref-type="fig"} shows the results of the LC-MS/MS chromatogram (A) and MS/MS spectrum of one identified peptide (B) from protein (8697 Da). Table [3](#T3){ref-type="table"} shows the results of identification of the three candidate protein biomarkers. They were haptoglobin alpha-1 chain (9190 Da) \[NCBI:P00738\], apolipoprotein C-I (6631 Da) \[NCBI:P02654\] and apolipoprotein C-III (8697 Da) \[NCBI:CAA25233\]. The whole sequence of the three candidate protein markers is given by combination of high sequence coverage and accurate molecular weight (MW) measurement using MALDI-TOF-MS.

###### 

Identification of the three potential protein biomarkers with identified peptides and covered sequence.

  ***m/z***   **Protein Name**       **Peptides Identified**     **Sequence\***
  ----------- ---------------------- --------------------------- ---------------------------------------------------------------------------------------
  9190        Haptoglobin α-chain    K.LRTEGDGVYTLNNEK.Q         addgcpkppeiahgyvehsv**ryqck nyyklrtegdgvytlnnekqwinka vgdklpeceavcgkpknpanpvq**
                                     R.YQCKNYYK.L                
                                     K.AVGDKLPECEAVCGK.P         
                                     K.QWINKAVGDK.L              
                                     R.TEGDGVYTLNNEK.Q           
                                     K.LPECEAYCGKPK.N            
                                     K.PKNPANPVQ.-               
  6631        Apolipoprotein C-I     G.TPDVSSALDK.L              **tpdvssaldklkefgntledkarelis rikqselsakmrewfsetfqk**vkeklkids
                                     K.EFGNTLEDKAR.E             
                                     K.LKEFGNTLEDK.A             
                                     R.EWFSETFQK.V               
                                     G. TPDVSSALDKLK.A           
                                     K.MREWFSETFQK.V             
                                     K.ARELISRIK.Q               
  8697        Apolipoprotein C-III   K.DALSSVQESQVAQQAR.G        seaedasllsfmqgymkhat**ktakdalssvq esqvaqqargwvtdgfsslkdywstvkd kfsefwdldpevrptsavaa**
                                     R.GWVTDGFSSLK.D             
                                     K.TAKDALSSVQESQVAQQAR.G     
                                     R.GWVTDGFSSLKDYWSTVK.D      
                                     K.DKFSEFWDLDPEVR.P          
                                     K.DKFSEFWDLDPEVRPTSAVAA.-   

\*: Bold letters show the covered sequence by identified peptide

![**Results of the identification of protein (8697 Da) by LC-MS/MS**. (A) Chromatogram of peptide mixture. (B) MS/MS spectrum of one peptide.](1476-4598-8-79-4){#F4}

Validation of three candidate protein biomarkers
------------------------------------------------

A ProteinChip-array-based immunoassay (Ciphergen Biosystems) was used to specifically capture haptoglobin alpha-1 chain, apolipoprotein C-I and apolipoprotein C-III from crude serum samples and to confirm the significance of each marker. The anti-haptoglobin alpha-chain antibody specifically captured the previously identified 9190 Da protein. The anti-apolipoprotein C-I array was developed to capture apolipoprotein C-I (6631 Da) and the apolipoprotein C-III antibody against specifically captured apolipoprotein C-III (8697 Da). (Figure [5](#F5){ref-type="fig"})

![**Representative spectra from ProteinChip array with specific immobilized antibodies**. (A) Representative spectra of the negative control (nonspecific rabbit IgG). (B) Representative spectra from ProteinChip array with anti-haptoglobin alpha chain antibody. (C) Representative spectra from ProteinChip array with anti-apolipoprotein C-I. (D) Representative spectra from ProteinChip array with anti-apolipoprotein C-III.](1476-4598-8-79-5){#F5}

Discussions
===========

In this study, we obtained serum protein mass spectra from PTC patients and controls using SELDI-TOF-MS. Based on the serum proteomic profiles, we constructed a classification model to discriminate PTC patients from non-cancer controls. One of the challenges in the analysis of SELDI-TOF-MS-generated data is to reduce the false protein peaks, in which the discriminatory power is due to random variation \[[@B20]\]. To solve this problem in the data processing of this experiment, we eliminated noise by discrete wavelength, identified mass-charge peaks of specimens using the method of local extremum, and clustered mass-charge peaks by setting 10% as the minimum threshold. Wilcoxon rank sum test analysis assessed the relative importance of each peak in the discrimination of 2 kinds of specimen according to *P*values. Furthermore, SVM was employed in our experiment, which is a kind of classification technology proposed by Vapnik and others. In the model discrimination, the popularization, model selection, overfitting, latitude disaster, and other problems of the small specimen model have been solved successfully in SVM \[[@B21]-[@B23]\]. The procedures included randomly combining the remarkably different mass-charge peaks and inputting them into SVM, screening out the markers, building the discrimination model, and then using the method of leave one out to assess the model by means of cross verification. By combination among these procedures mentioned above, the popularization of the model building and the accuracy of the prediction were ensured. The classification model could discriminate patients with PTC from non-cancer controls with a sensitivity of 95.15% and a specificity of 93.97% in the blind testing set. The up-regulated candidate protein biomarker was identified as haptoglobin alpha-1 chain (9190 Da). Another two down-regulated candidate protein biomarkers (6631 and 8697 Da) were identified as apolipoprotein C-I and apolipoprotein C-III.

Among the proteins identified by LC-MS/MS, haptoglobin alpha-1 chain was significantly elevated in PTC patients and this protein may play a critical role in the development of PTC. Intact haptoglobin, composed of two different polypeptides (alpha and beta-chains), is an acute phase protein capable of binding haemoglobin and preventing iron loss \[[@B24]\]. It was reported that body iron could promote neoplastic cell growth and accumulate in cancer cells more than in normal cells \[[@B25]\]. Furthermore, a few other studies have demonstrated that there is a higher cancer risk in patients with larger iron stores than those with small iron stores \[[@B26]\]. Collectively, highly expressed haptoglobin results in a high hemoglobin/iron existence and raises the possibility of a causative involvement of iron-derived oxidative stress in the tumour development. Recently, there are several reports in the literature showing increased expression of haptoglobin in ovarian cancer, prostatic carcinoma and pancreatic cancer \[[@B27]-[@B29]\], and the level of haptoglobin alpha chain up-regulated in serum of breast cancer \[[@B30]\]. However, it is necessary to understand more clearly of the role of haptoglobin alpha-1 chain in the development of PTC through further studies of biological mechanisms of thyroid carcinoma.

Apolipoproteins (APOs) are lipid carriers and previous studies about APO mainly focused on lipoprotein metabolism. Recently, APOs have been reported to regulate many cellular function. For example, the protein kinase Akt can be elicited by APO C-I, which in turn promotes growth factor-mediated cell survival and block apoptosis \[[@B31]\]. In this study, the APO C-I is down-regulated in the serum of PTC patients, which indicates that APO C-I may be related to PTC. Thus, besides the function of APO C-I in lipid metabolism, additional function of APO C-I in cancerogenesis may also exist. However, the mechanism of how APO C-I is degraded in PTC is not very clear, and further research is required. APO C-III is primarily synthesized in the liver and in a minor degree in the small intestine. The regulatory elements that control both hepatic and intestinal transcription of the human APO C-III gene are localized between nucleotides -792 and -25 of the APO C-III promoter. The mechanism of why APO C-III was decreased in PTC may be as follows. Orphan members of the nuclear hormone receptor superfamily can bind to the hormone response elements (HREs), and strongly enhance or repress APO C-III promoter\'s activity. It was reported that a combination of RXRalpha and T3Rbeta could repress the APO C-III promoter\'s activity in the presence of T3 \[[@B32]\]. In addition, the thyroid stimulating hormone (TSH) level was significantly higher in PTC than in non-cancer control \[[@B33]\], correspondingly, T3 increased, thus the expression of APO C-III was possibly inhibited in PTC patients.

Conclusion
==========

In summary, we have identified a set of protein peaks that could discriminate PTC from non-cancer controls. From the protein peaks specific for PTC disease, we identified haptoglobin alpha-1 chain, apolipoprotein C-I and apolipoprotein C-III as potential proteomic biomarkers of PTC. Further studies with larger sample sizes will be needed to verify the specific protein markers. An efficient strategy, composed of SELDI-TOF-MS analysis, HPLC purification, MALDI-TOF-MS trace and LC-MS/MS identification has been proved very successful.

Materials and methods
=====================

Patients and serum samples
--------------------------

Serum samples were obtained from 224 individuals with informed consent in the Department of General Surgery, the First Affiliated Hospital of Zhengzhou University. These 224 individuals included 108 patients with PTC, 56 patients with benign thyroid node, and 60 healthy individuals. Patients with PTC had a median age of 43 years (ranging from 23 to 75 years, 27 men and 81 women), and the sera was obtained at the time of diagnosis. All 108 patients were distributed in 4 stages according to UICC. In stage I there were 85 patients, stage II, III & IV consisted of 12, 8 & 3 patients respectively. The diagnosis, stage and other information about these patients are listed in Table [4](#T4){ref-type="table"} and Table [5](#T5){ref-type="table"}. Inclusion criteria for the study were patients with a confirmed diagnosis of PTC, the ability to provide written, informed consent, and without any previous treatment. Patients with benign thyroid node and healthy donors were defined as controls in this study. The benign thyroid node group and the healthy individual group were age- and gender-matched with the PTC group. Pathological diagnosis of all the PTC and benign thyroid nodes were confirmed independently by two pathologists. All serum samples were collected preoperatively in the morning before breakfast. The sera were left at room temperature for 1 h, centrifuged at 3000 rpm for 10 min, and then stored at -80°C.

###### 

The diagnosis, staging and other information about PTC patients in the training set.

  **Patient ID**       **Age (years)**   **Sex (F = female M = male)**   **Diagnosis**   **Stage**   **Tumor size (cm)**   **Cervial lymph node metastasis**   **Distant metastases**
  -------------------- ----------------- ------------------------------- --------------- ----------- --------------------- ----------------------------------- ---------------------------
  Patients\<45 years                                                                                                                                           
  P38                  23.01             F                               PTC             I           0.5                   None                                NO
  P78                  29.98             F                               PTC             I           1.0                   None                                NO
  P65                  32.12             F                               PTC             I           1.0                   None                                NO
  P81                  36.45             F                               PTC             I           0.8                   None                                NO
  P36                  38.50             F                               PTC             I           0.5                   None                                NO
  P43                  39.56             F                               PTC             I           1.0                   None                                NO
  P16                  40.05             F                               PTC             I           0.8                   None                                NO
  P44                  40.11             M                               PTC             I           1.0                   Yes(VI lymph node)                  NO
  P37                  40.25             F                               PTC             I           1.6                   None                                NO
  P5                   40.36             F                               PTC             I           1.0                   None                                NO
  P18                  40.50             M                               PTC             I           0.6                   None                                NO
  P80                  40.81             M                               PTC             I           0.7                   None                                NO
  P93                  40.90             F                               PTC             I           1.0                   None                                NO
  P67                  41.00             F                               PTC             I           1.0                   None                                NO
  P46                  41.08             F                               PTC             I           1.5                   None                                NO
  P9                   41.10             M                               PTC             I           1.8                   Yes(VI lymph node)                  NO
  P35                  41.26             M                               PTC             I           1.0                   None                                NO
  P47                  41.38             F                               PTC             I           0.8                   None                                NO
  P13                  41.44             F                               PTC             I           1.0                   None                                NO
  P6                   41.52             M                               PTC             I           0.6                   None                                NO
  P17                  41.55             F                               PTC             I           1.5                   Yes(VI lymph node)                  NO
  P40                  41.62             F                               PTC             I           0.8                   None                                NO
  P64                  41.71             F                               PTC             I           0.8                   None                                NO
  P111                 41.89             M                               PTC             I           1.3                   None                                NO
  P69                  42.14             M                               PTC             I           1.2                   None                                NO
  P2                   42.25             F                               PTC             I           1.6                   Yes(VI lymph node)                  NO
  P12                  42.36             F                               PTC             I           0.8                   None                                NO
  P7                   42.56             F                               PTC             I           0.8                   None                                NO
  P4                   42.73             M                               PTC             I           0.6                   None                                NO
  P49                  43.20             F                               PTC             I           1.2                   None                                NO
  P8                   43.66             M                               PTC             I           1.5                   Yes(VI lymph node)                  NO
  P70                  43.80             F                               PTC             I           0.7                   None                                NO
  P42                  44.10             F                               PTC             I           1.5                   None                                NO
  P114                 44.30             M                               PTC             I           0.8                   None                                NO
  P83                  44.45             F                               PTC             I           1.3                   None                                NO
  P99                  44.60             M                               PTC             I           0.6                   None                                NO
  Patients\>45 years                                                                                                                                           
  P105                 45.05             F                               PTC             I           0.8                   None                                NO
  P71                  45.58             M                               PTC             II          2.5                   None                                NO
  P107                 45.75             M                               PTC             I           0.7                   None                                NO
  P60                  45.81             F                               PTC             II          2.5                   None                                NO
  P10                  46.48             F                               PTC             I           0.8                   None                                NO
  P104                 46.40             F                               PTC             II          2.3                   None                                NO
  P14                  46.90             F                               PTC             II          2.5                   None                                NO
  P52                  47.10             F                               PTC             I           0.7                   None                                NO
  P11                  47.64             M                               PTC             III         3.5                   Yes(VI lymph node)                  NO
  P88                  47.89             F                               PTC             I           0.6                   None                                NO
  P22                  48.50             F                               PTC             I           0.8                   None                                NO
  P73                  48.81             M                               PTC             I           0.7                   None                                NO
  P87                  49.56             F                               PTC             III         4.5                   Yes(VI lymph node)                  NO
  P100                 49.89             F                               PTC             II          2.8                   None                                NO
  P25                  50.25             F                               PTC             III         3.8                   Yes(VI lymph node)                  NO
  P85                  50.89             F                               PTC             I           0.7                   None                                NO
  P101                 57.14             M                               PTC             II          2.5                   None                                NO
  P32                  58.21             F                               PTC             II          2.3                   None                                NO
  P103                 60.10             F                               PTC             I           0.8                   None                                NO
  P53                  61.12             F                               PTC             II          2.5                   None                                NO
  P23                  65.84             F                               PTC             IV          4.0                   Yes(hibateral)                      Yes(pulmonary metastasis)
  P54                  68.19             F                               PTC             IV          3.5                   Yes(mediastinal)                    Yes(osseous metastasis)
  P24                  72.31             F                               PTC             III         3.6                   None                                NO
  P63                  74.98             F                               PTC             IV          3.5                   Yes(hibateral)                      Yes(pulmonary metastasis)

###### 

The diagnosis, staging and other information about PTC patients in the blind testing set.

  **Patient ID**       **Age (years)**   **Sex (F = female M = male)**   **Diagnosis**   **Stage**   **Tumor size (cm)**   **Cervial lymph node metastasis**   **Distant metastases**
  -------------------- ----------------- ------------------------------- --------------- ----------- --------------------- ----------------------------------- ------------------------
  Patients\<45 years                                                                                                                                           
  P57                  25.50             F                               PTC             I           0.6                   None                                NO
  P64                  41.71             F                               PTC             I           0.8                   None                                NO
  P15                  31.25             F                               PTC             I           0.5                   None                                NO
  P19                  34.16             F                               PTC             I           0.6                   None                                NO
  P79                  37.71             F                               PTC             I           0.7                   None                                NO
  P91                  38.63             F                               PTC             I           1.2                   Yes (VI lymph node)                 NO
  P110                 39.80             F                               PTC             I           1.0                   None                                NO
  P34                  40.20             F                               PTC             I           0.6                   None                                NO
  P66                  40.28             M                               PTC             I           0.7                   None                                NO
  P92                  40.42             F                               PTC             I           1.0                   None                                NO
  P109                 40.56             F                               PTC             I           0.5                   None                                NO
  P1                   40.85             F                               PTC             I           0.7                   None                                NO
  P94                  41.15             F                               PTC             I           0.7                   None                                NO
  P108                 41.30             F                               PTC             I           1.6                   Yes (VI lymph node)                 NO
  P95                  41.39             M                               PTC             I           1.2                   None                                NO
  P68                  41.46             F                               PTC             I           0.8                   None                                NO
  P106                 41.58             M                               PTC             I           1.5                   None                                NO
  P96                  41.66             F                               PTC             I           0.7                   None                                NO
  P30                  41.82             F                               PTC             I           1.0                   None                                NO
  P39                  42.05             F                               PTC             I           1.0                   None                                NO
  P41                  42.20             F                               PTC             I           1.8                   None                                NO
  P89                  42.31             M                               PTC             I           0.7                   None                                NO
  P48                  42.45             M                               PTC             I           1.2                   None                                NO
  P98                  42.68             F                               PTC             I           1.5                   None                                NO
  P113                 42.80             F                               PTC             I           0.9                   None                                NO
  P97                  43.40             F                               PTC             I           1.0                   None                                NO
  P29                  43.72             F                               PTC             I           1.6                   Yes (VI lymph node)                 NO
  P90                  44.26             M                               PTC             I           0.8                   None                                NO
  P50                  44.54             F                               PTC             I           0.7                   None                                NO
  P56                  44.98             F                               PTC             I           0.7                   None                                NO
  Patients\>45 years                                                                                                                                           
  P28                  45.52             F                               PTC             I           0.8                   None                                NO
  P27                  45.66             F                               PTC             II          2.8                   None                                NO
  P51                  46.05             F                               PTC             I           0.6                   None                                NO
  P55                  46.62             M                               PTC             I           0.8                   None                                NO
  P72                  46.85             F                               PTC             II          2.8                   None                                NO
  P84                  47.25             F                               PTC             I           0.6                   None                                NO
  P33                  48.30             F                               PTC             I           0.8                   None                                NO
  P102                 48.73             F                               PTC             III         3.8                   Yes (VI lymph node)                 NO
  P31                  49.14             F                               PTC             I           0.6                   None                                NO
  P20                  49.60             F                               PTC             I           0.9                   None                                NO
  P61                  49.91             M                               PTC             I           0.8                   None                                NO
  P77                  50.40             F                               PTC             I           0.8                   None                                NO
  P21                  52.30             F                               PTC             I           0.9                   None                                NO
  P74                  54.56             M                               PTC             III         3.5                   Yes (VI lymph node)                 NO
  P62                  56.05             F                               PTC             III         3.5                   Yes (VI lymph node)                 NO
  P86                  62.13             M                               PTC             II          2.8                   None                                NO
  P75                  67.40             F                               PTC             II          2.5                   None                                NO
  P76                  68.56             F                               PTC             III         3.8                   None                                NO

Reagents and instruments
------------------------

Sinapinic acid (SA) was purchased from Fluka (USA). ProteinChip Biosystems (Ciphergen PBS II plus SELDI-TOFMS) and WCX2 chip were purchased from Ciphergen Biosystems (USA). All other SELDI-TOF-MS related reagents were acquired from Sigma (USA). Ziptip C18 was purchased from Millipore (USA). Trypsase was purchased from Promega (USA). IAM was purchased from AppliChem (GER). DTT was purchased from BIO-RAD (GER). MALDI-TOF-MS was purchased from Kratos Analytical Co (UK) and HPLC was purchased from Shimadzu (JPN). LC-MS/MS was purchased from Thermo Electron Corporation (USA).

SELDI-TOF-MS analysis of serum protein profiles
-----------------------------------------------

Protein profiling of serum samples was determined by SELDI-TOF-MS using the WCX2 (weak cation exchange) Proteinchip arrays (Ciphergen Biosystems, USA). Frozen serum samples were defrosted on ice and spun at 10 000 rpm for 5 min at 4°C. Each serum sample (10 μl) was denatured by addition of 20 μl of U9 buffer (9 M urea, 2% CHAPS, 50 mM Tris-HCI, 1% DTT, PH 9.0) and vortexed at 4°C for 30 min. Each sample was then diluted in 108 μl of low stringency buffer (0.1 M sodium acetate, PH 4.0) and 100 μl of each diluted serum sample was hybridized with WCX2 proteinchip arrays, which was held by a bioprocessor (Ciphergen Biosystems) and preactivated twice with 150 μl low stringency buffer at room temperature for 5 min. The diluted serum sample was added on the surface of the WCX2 chip for 60 min at room temperature. Each spot was then washed three times with appropriate buffers of various PHs and ionic strengths to eliminate non-adsorbed proteins. After drying the array surface in the air, 1 μl saturated sinapinic acid (SA) matrix in 50% ACN and 0.5% TFA was applied and allowed to dry. MS analysis was performed on a PBS-II ProteinChip reader (Ciphergen Biosystems). Mass peak detection was analyzed using ProteinChip Biomarker Software version 3.1 (Ciphergen Biosystems). The mass spectra of the proteins were generated using an average of 140 laser shots at a laser intensity of 170 arbitrary units and detector sensitivity was set at 6. For data acquisition of low-molecular- weight proteins, the optimize detection mass range was set from 2 to 20 kDa for all study sample profiles. The instrument was calibrated by the All-in-one peptide molecular mass standard (Ciphergen Biosystems).

Bioinformatics and biostatistics
--------------------------------

Patients with PTC were split into a training set and a blind testing set. Sixty samples of PTC patients (45 stage I, 8 stage II, 4 stage III, 3 stage IV) and 40 healthy controls were selected for a training sample set randomly. To evaluate the accuracy and validity of the classification model, the remaining 48 samples of PTC patients (40 stage I, 4 stage II, 4 stage III) and 76 controls (20 healthy controls and 56 patients with benign thyroid node) were selected for a blind testing set. (Table [6](#T6){ref-type="table"}).

###### 

Study population used in SELDI experiment

                 **PTC Patients**   **Controls**         **Total**
  -------------- ------------------ -------------------- -----------
  Training set   60                 40 h\*               100
  Testing set    48                 76(20 h\*+56p\*\*)   124
                                                         
  Total          108                116                  224

h\*: Healthy controls

p\*\*: Patients with benign thyroid node

The first step of data analysis was to use the undecimated discrete wavelet transform (UDWT) method to denoise the signals. Secondly, the spectra were subjected to baseline correction by aliging with a monotone local minimum curve and mass calibration. The proteomic peaks were detected and quantified by an algorithm that takes the maximal height of every denoised, baseline-corrected, and calibrated mass spectrum into account. Thirdly, the peaks were filtered to maintain a S/N of more than three. The S/N of a peak is the ratio of the height of the peak above the baseline to the wavelet-defined noise. Finally, to match peaks across spectra, we pooled the detected peaks if the relative difference in their mass sizes was not more than 0.3%. The minimal percentage of each peak, appearing in all the spectra, is specified to ten. The matched peak across spectra is defined as a peak cluster. If a spectrum does not have a peak within a given cluster, the maximal height within the cluster will be assigned to its peak value. The normalization was performed only with the identified peak clusters.

To distinguish between data of different groups, we used a nonlinear SVM classifier, originally developed by Vladimir Vapnik, with a radial-based function kernel, a parameter Gamma of 0.6, and a cost of the constrain violation of 19. The leave-one-out crossing validation approach was applied to estimate the accuracy of this classifier. The capability of each peak in distinguishing data of different groups was estimated by the *p*value of Wilcoxson *T*-test. The *p*value was set at 0.01 to be statistically significant. The remaining 48 samples of PTC patients and 76 controls (20 healthy controls and 56 patients with benign thyroid node), were analyzed to test the classification model. PTC and control samples were then discriminated based on their proteomic profile characteristics. The sensitivity was defined as the probability of predicting PTC cases, the specificity was defined as the probability of predicting control samples. The positive predictive value was defined as the probability of PTC if a test result was positive.

Serum fractionation
-------------------

Serum samples both from healthy controls and PTC patients were selected for the purification of the three candidate protein biomarkers. The serum sample was mixed with U9 buffer (1:2, v/v) and incubated for 30 min at room temperature. The sample was then diluted in 5 mL WCX binding buffer (50 mM NaAc, pH 4.0) and loaded to the CM Ceramic Hyper D WCX SPE column (6 × 10 mm, Pall Life science, USA). After washing with 2 mL of WCX binding buffer, the column was eluted with 5 ml of eluting buffer (2 M NaCl, 50 mM NaAc, pH 4.0) at a flow rate of 0.5 ml/min. The eluted fraction was further purified using HPLC.

Purification of candidate protein markers using HPLC
----------------------------------------------------

HPLC separation was performed using SCL-10AVP (Shimadzu, Japan) with a Sunchrom C18 column (250 × 4.6 mm, 5 μm particle size, 300 Å) (The Great Eur-Asia Sci-Tech Development Co. Ltd, Beijing, China) and a C18 guard column (10 × 3 mm, Shimadzu, Japan). The mobile phase consisted of solvent A (5% ACN, 0.1% TFA) and solvent B (90% ACN, 0.1% TFA). The HPLC separation was achieved with a linear solvent gradient: 100% A (0 min)-15% B (15 min)-65% B (65 min)-100% B (100 min) at a flow-rate of 0.5 ml/min. The eluate was detected at multiple wavelengths of 214, 254, 280 nm. Each peak fraction was collected and concentrated using SpeedVac, and then analyzed using AXIMA-CFRTM plus MALDI-TOF mass spectrometer (Shimadzu/Kratos, Manchester, UK) in linear mode to trace the candidate protein biomarkers with α-cyano-4-hydrorycinnamic acid (CHCA) as matrix.

Identification of candidate protein biomarkers by LC-MS/MS
----------------------------------------------------------

In-solution digestion of each concentrated fraction, which contains one candidate protein biomarker, was performed with a standard protocol. Briefly, each fraction was dissolved in 25 mM NH~4~HCO~3~, and reduced with 10 mM DTT for 1 hour, alkylated by 40 mM iodoacetamide in the dark for 45 min at room temperature, and then 40 mM DTT was added to quench the iodoacetamide for 30 min at room temperature. Then proteins were proteolysed with 20 ng of modified trypsin (Promega, Madison, WI) in 25 mM NH~4~HCO~3~overnight at 37°C. The supernatant was collected and peptides were further extracted in 0.1% acetic acid and 60% acetonitrile. Peptide extracts were vacuumdried and resuspended in 20 μl of water for mass analysis. Protein digests obtained above were loaded onto a home-made C18 column (100 mm × 100 μm) packed with Sunchron packing material (SP-120-3-ODS-A, 3 μm) and followed with nano-LC-ESI-MS/MS analysis. The LTQ mass spectrometer was operated in a data-dependent mode, in which the initial MS scan recorded the *m/z*ratios of ions over the mass range from 400-2000 Da firstly, and then the five most abundant ions were automatically selected for subsequent collision-activated dissociation. All MS/MS data were searched against a human protein database downloaded from NCBI using the SEQUEST program (Thermo, USA).

Confirmation of candidate protein biomarkers using ProteinChip Immunoassays
---------------------------------------------------------------------------

To confirm the identity of the candidate protein biomarkers, all samples from the initial experiments were reanalyzed by using ProteinChip immunoassays (Ciphergen Biosystems). Specific antibody arrays were prepared by covalently coupling the appropriate antibodies to preactivated ProteinChip arrays (Ciphergen Biosystems). Antibodies (anti-human haptoglobin alpha-chain, ms1750rb-h; anti-human apolipoprotein C-I, ab9106; anti-human apolipoprotein C-III, mab002-74/3) were covalently coupled to PS20 arrays, respectively. After blocking with BSA and washing to remove uncoupled antibodies, antibody-coated spots were incubated with 1.5 μL of serum samples and 3 μL of binding buffer (0.1 M Na~3~PO~4~, 0.5 M urea, 0.5% CHAPS, pH 7.2) for 90 min. Spots were then washed with PBST (0.5% Triton X-100), PBS and deionized water twice respectively before drying. SELDI-TOF-MS analysis was performed on a PBS-II ProteinChip reader with CHCA as matrix.

Abbreviations
=============

**PTC**: papillary thyroid carcinoma; **SELDI-TOF-MS**: surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy; ***m/z***: mass to charge; **HPLC**: high Performance Liquid Chromatography; **LC-MS/MS**: liquid chromatography tandem mass spectrometry; **MALDI-TOF-MS**: matrix-assisted laser desorption/ionization time-of-flight mass spectroscopy; **WCX**: weak cation exchange; **SVM**: support vector machine; **S/N**: signal to noise ratio; **NCBI**: national center for biotechnology information.
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